Arbekacin

Arbekacin
Clinical data
Trade names	Habekacin
AHFS/Drugs.com	International Drug Names
Routes of; administration	Intramuscular, intravenous
Drug class	Aminoglycoside antibiotic
ATC code	J01GB12 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Metabolism	minimal
Excretion	Renal
Identifiers
	IUPAC name (2S)-4-Amino-N-[(1R,2S,3S,4R,5S)-5-amino-4-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide;
CAS Number	51025-85-5 ;
PubChem CID	68682;
DrugBank	DB06696 ;
ChemSpider	9573665 ;
UNII	G7V6SLI20L;
KEGG	D07462 ;
ChEMBL	ChEMBL426926 ;
PDB ligand	84G (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID8048319 ;
Chemical and physical data
Formula	C22H44N6O10
Molar mass	552.626 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C[C@H]([C@H](O[C@@H]1CN)O[C@@H]2[C@H](C[C@H]([C@@H]([C@H]2O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)N)O)NC(=O)[C@H](CCN)O)N)N;
	InChI InChI=InChI=1S/C22H44N6O10/c23-4-3-12(30)20(34)28-11-5-10(26)18(37-21-9(25)2-1-8(6-24)35-21)17(33)19(11)38-22-16(32)14(27)15(31)13(7-29)36-22/h8-19,21-22,29-33H,1-7,23-27H2,(H,28,34)/t8-,9+,10-,11+,12-,13+,14-,15+,16+,17-,18+,19-,21+,22+/m0/s1 ; Key:MKKYBZZTJQGVCD-XTCKQBCOSA-N ;
	(what is this?) (verify)

Arbekacin (INN) is a semisynthetic aminoglycoside antibiotic which was derived from kanamycin. It is primarily used for the treatment of infections caused by multi-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA). Arbekacin was originally synthesized from dibekacin in 1973 by Hamao Umezawa and collaborators. It has been registered and marketed in Japan since 1990 under the trade name Habekacin. Arbekacin is no longer covered by patent and generic versions of the drug are also available under such trade names as Decontasin and Blubatosine.